Today, on January 31st, investors have the chance to spice up their portfolio with three sizzling hot stocks exhibiting strong momentum and a buy rank. Read on for some high-octane investment opportunities.
ADMA Biologics, Inc.
ADMA Biologics, a leading biopharmaceutical company, has been charging ahead with a Zacks Rank #1, propelling its current year earnings estimate up by a whopping 33.3% over the past 60 days.
Over the last three months, ADMA’s shares have zoomed up by 52%, leaving the S&P 500’s 16.1% gain in the rearview mirror. The company boasts a Momentum Score of A.
Ekso Bionics Holdings, Inc.
Ekso Bionics Holdings is not lagging behind either, with a Zacks Rank #1 and a solid 25.6% surge in its current year earnings estimate over the previous 60 days.
Over the same period, Ekso Bionics witnessed its shares spiking by 56.9%, outperforming the S&P 500. The company holds a Momentum Score of A.
Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics comes charging in with a Zacks Rank #1 and a hefty 16% surge in its current year earnings estimate over the prior 60 days.
Not to be outdone, Inhibikase saw its shares rocketing up by an astonishing 270.6%, leaving the S&P 500’s gain of 16.1% trailing in the dust. The company’s Momentum Score stands at B.
Find the full list of top ranked stocks here and learn more about the Momentum score and how it is calculated here.
Just Released: Zacks Top 10 Stocks for 2024
Do you want to hit the gas on your investments? The Zacks Top 10 Stocks for 2024 has been setting the track on fire. From inception in 2012 through November 2023, the top 10 stocks cruised to a sizzling gain of +974.1%, leaving the S&P 500’s +340.1% in the dust. Jump on board early and take the inside lane on these high-octane stocks with enormous potential.
Please note that the views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
